Soma Pharmacy Blognews

Exercise Eases Patellofemoral Pain (CME/CE)
Exercise supervised by a physical therapist was more effective for pain and function than rest and avoidance of stress on the knee in patients with patellofemoral pain syndrome, a randomized Dutch study found.

Study: No Benefit to Costly Arthritis Drugs
For many people with rheumatoid arthritis, the much cheaper traditional, disease-modifying anti-rheumatic drugs (DMARDs) appear to work just as well as newer TNF blockers that target the underlying disease process, a large study shows.

CDC: Partial OK of Gardasil for Boys
Parents of boys may get federal funds to pay for the Gardasil HPV vaccine to prevent sexually transmitted genital warts, a CDC advisory panel has ruled.

Obese Women Retain More Pregnancy Weight
Obese women who gain more weight than they should during pregnancy are more likely to keep the weight on afterward.

Mutant Gene Raises Risk of Parkinson’s Disease
People with a rare disease called Gaucher’s disease have a high risk of developing Parkinson’s disease. That clue led scientists to discover gene mutations that raise the risk of Parkinson’s fivefold.

Glucosamine May Not Fight Osteoarthritis
Using a more sensitive measure of joint damage than in the past, researchers have found that the popular supplement glucosamine does not appear to slow the progression of knee osteoarthritis.

Drugs May Save Memory of the Sleep-Deprived
Drugs that block an enzyme called PDE4 may override memory problems stemming from sleep deprivation, researchers report.

EMEA informs Antigenics on a negative opinion for Oncophage MAA
Antigenics Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP), of the European Medicines Agency (EMEA), has verbally informed the Company at an oral meeting to anticipate a negative opinion on the marketing authorization application (MAA) for Oncophage (vitespen) in early-stage, localized [...]

Lux Biosciences to present on LX211 at 2009 AAO annual conference
Lux Biosciences, Inc., a privately held biotechnology company focused on the development and commercialization of therapies for serious ophthalmic diseases, today announced that the company’s experimental drug LX211 (LUVENIQ; oral voclosporin) will be featured in several presentations at the 2009 American Academy of Ophthalmology annual [...]

Swine flu vaccines arrive at health departments, hospitals and community vaccinator facilities
The swine flu (H1N1)Vaccine is starting to arrive at health departments, hospitals, and community vaccinator facilities.